A Study Related to the VOYAGER PAD Trial to Learn More About the Target Population for Xarelto in French Patients
NCT ID: NCT04824729
Last Updated: 2022-04-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
227613 participants
OBSERVATIONAL
2021-03-24
2022-01-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In a previous Bayer trial called VOYAGER PAD, researchers studied Xarelto in participants with PAD who had recently had a revascularization procedure in their lower leg. The researchers studied how well Xarelto worked and how safe it was in these participants.
Based on the results of the VOYAGER PAD trial, the researchers in this study want to learn the number of patients with PAD who had a revascularization procedure in France from January 1st, 2016 to December 31st, 2019. This can help the researchers learn more about the target population (a specific group of people) who could potentially receive treatment with Xarelto.
Xarelto is available for doctors in France to prescribe to patients who have the following conditions:
* to reduce the risk of another heart attack or of dying from a disease related to the heart or the blood vessels in adults with acute coronary syndrome (a group of conditions that includes heart attack and unstable angina, a severe type of chest pain) who have had an increase in certain cardiac blood tests
* to reduce the risk of getting blot clots (atherothrombotic events) in adults at a high risk of getting a blood clot due to a coronary artery disease or peripheral artery disease which causes symptoms
* to prevent blood clots in the veins after a hip or knee replacement operation in adults
* to prevent blood clots in brain (stroke) and other blood vessels in the body in adults who have a form of irregular heart rhythm called non-valvular atrial fibrillation
* to treat blood clots in the veins of the legs (deep vein thrombosis) and in the blood vessels of the lungs (pulmonary embolism), and to prevent blood clots from re-occurring in the blood vessels of the legs and/or lungs in adults
* to treat blood clots and prevent re-occurrence of blood clots in the veins or in the blood vessels of the lungs in full-term newborn babies, infants and toddlers, children and adolescents below 18 years following an initial treatment of at least 5 days with injectable medicines used to treat blood clots
All the patients in this study will have PAD in their lower leg. They will all have had a revascularization procedure during a hospital stay in France between January 1st, 2016 and December 31st, 2019. The researchers will collect the patients' health data from the French National Health Insurance (NHI) hospital discharge database (PMSI). The researchers will look at the health data from all patients with PAD who had a revascularization procedure and also patients who could have joined the VOYAGER PAD trial. This group will not include any patients who have health conditions other than PAD.
The researchers will review each patient's medical records until December 31st, 2019 or earlier if the patient has died. The researchers will also look at any previous medical records from the date of each patient's revascularization procedure back to January 1st, 2014. The researchers will use these medical records to look for any health conditions other than PAD that the patients may have had before their revascularization procedure after January 1st 2016.
The main question the researchers want to answer in this study is: how many patients with PAD had a revascularization procedure between January 1st, 2016 and December 31st, 2019?
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Outpatient Hospitalization of Unaccompanied Patients at Home for Endovascular Treatment of Peripheral Arterial Disease.
NCT05756491
Assessment of the Sub-gonal Arterial Revascularization of the Lower Limbs in Critical Ischemia by Venous Allograft Stored at + 4 ° C (ERAV)
NCT05101512
Endovascular Treatment of Peripheral Artery Disease (PAD)
NCT03414515
Atherectomy Followed by a Drug Coated Balloon to Treat Peripheral Arterial Disease
NCT01366482
Elutax-SV Drug-eluting Balloons for Below-the-knee Treatment
NCT02539940
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
French PAD revascularized population
Patients with lower-extremity peripheral artery disease (PAD) who have undergone lower limb revascularization (PAD revascularized population) in France from 2016 to 2019.
Lower limb revascularization
French population of patients with lower-extremity peripheral artery disease who have undergone lower limb revascularization.
French VOYAGER PAD-like population
VOYAGER PAD-like patients in France from 2016 to 2019.
This population will be constituted to fit the VOYAGER PAD clinical trial population. It will be created using the VOYAGER PAD exclusion criteria and resembles a subgroup of the PAD revascularized population.
Lower limb revascularization
French population of patients matching the VOYAGER PAD exclusion criteria resembling a subgroup of the PAD revascularized population.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lower limb revascularization
French population of patients with lower-extremity peripheral artery disease who have undergone lower limb revascularization.
Lower limb revascularization
French population of patients matching the VOYAGER PAD exclusion criteria resembling a subgroup of the PAD revascularized population.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient with a lower-extremity PAD.
* Patient with a lower limb revascularization procedure.
Exclusion Criteria
* Patients presenting the following medical history at index date will be excluded from the VOYAGER PAD-like population.:
* Prior revascularization within 10 days of the qualifying lower limb revascularization
* ALI within 2 weeks prior to the qualifying lower limb revascularization
* Patients with major tissue loss (defined as significant ulceration/gangrene proximal to the metatarsal heads, i.e. heel or midfoot)
* Atrial fibrillation and flutter
* Mechanical valve history
* History of hemorrhage
* Chronic hepatic failure (Any known hepatic disease associated with coagulopathy or bleeding risk)
* Gastrointestinal ulcer
* Oesophageal varices
* Dialysis
* Confirmed Acute Coronary Syndrome (ACS) within 30 days prior to lower limb revascularization
* Any history of intracranial hemorrhage, stroke, or transient ischemic attack (TIA)
* Known active malignancy, excluding local skin cancer (basal or squamous cell carcinoma)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
External supplier: HEVA
UNKNOWN
Bayer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
PMSI
Multiple Locations, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
21849
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.